{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:35:48Z","timestamp":1781498148042,"version":"3.54.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007427","name":"Research Institute for Endocrine Sciences","doi-asserted-by":"publisher","award":["24977-ERC-2020"],"award-info":[{"award-number":["24977-ERC-2020"]}],"id":[{"id":"10.13039\/501100007427","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Medical Sciences"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.advms.2021.12.003","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T13:01:38Z","timestamp":1641387698000},"page":"79-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["To what extent does polycystic ovary syndrome influence the cut-off value of prolactin? Findings of a community-based study"],"prefix":"10.1016","volume":"67","author":[{"given":"Fatemeh","family":"Mahboobifard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Rahmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Amiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fereidoun","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahimeh","family":"Ramezani Tehrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.advms.2021.12.003_bib1","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/humrep\/dep399","article-title":"The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria","volume":"25","author":"March","year":"2010","journal-title":"Hum Reprod"},{"key":"10.1016\/j.advms.2021.12.003_bib2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/AOG.0000000000002698","article-title":"Polycystic ovary syndrome","volume":"132","author":"Azziz","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.advms.2021.12.003_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","year":"2004","journal-title":"Hum Reprod"},{"key":"10.1016\/j.advms.2021.12.003_bib4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.advms.2021.12.003_bib5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1055\/s-2002-36709","article-title":"Hyperprolactinemia: etiology, diagnosis, and management","volume":"20","author":"Mah","year":"2002","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.advms.2021.12.003_bib6","first-page":"213","article-title":"Physiological and pathological hyperprolactinemia: can we minimize errors in the clinical practice","author":"L\u00f3pez","year":"2013","journal-title":"Prolactin. Rijeka, Croatia: InTech"},{"key":"10.1016\/j.advms.2021.12.003_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/1179558119871921","article-title":"PCOS and Hyperprolactinemia: what do we know in 2019?","volume":"13","author":"Delcour","year":"2019","journal-title":"Clin Med Insights Reprod Health"},{"key":"10.1016\/j.advms.2021.12.003_bib8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0002-9378(15)30642-6","article-title":"Amenorrhea associated with bilateral polycystic ovaries","volume":"29","author":"Stein","year":"1935","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.advms.2021.12.003_bib9","first-page":"197","article-title":"Hyperprolactinaemia in polycystic ovary syndrome","volume":"70","author":"Lunde","year":"1981","journal-title":"Ann Chir Gynaecol"},{"key":"10.1016\/j.advms.2021.12.003_bib10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0015-0282(16)44845-4","article-title":"Polycystic ovarian disease associated with hyperprolactinemia and defective metoclopramide response","volume":"34","author":"Alger","year":"1980","journal-title":"Fertil Steril"},{"key":"10.1016\/j.advms.2021.12.003_bib11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0015-0282(16)46633-1","article-title":"The hyperprolactinemic polycystic ovary syndrome may not be an distinct entity","volume":"38","author":"Corenblum","year":"1982","journal-title":"Fertil Steril"},{"key":"10.1016\/j.advms.2021.12.003_bib12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000291850","article-title":"Endocrinological and clinical analysis of hyperprolactinemic patients with and without ultrasonically diagnosed polycystic ovarian changes","volume":"43","author":"Isik","year":"1997","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.advms.2021.12.003_bib13","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.jocn.2015.03.058","article-title":"Update on prolactinomas. Part 1: clinical manifestations and diagnostic challenges","volume":"22","author":"Wong","year":"2015","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.advms.2021.12.003_bib14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/09513590.2010.487606","article-title":"Polycystic ovary syndrome or hyperprolactinaemia: a study of mild hyperprolactinaemia","volume":"27","author":"Su","year":"2011","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"10.1016\/j.advms.2021.12.003_bib15","first-page":"53","article-title":"Prolactin secretion in polycystic ovary syndrome (PCOS)","volume":"36","author":"Szosland","year":"2015","journal-title":"Neuroendocrinol Lett"},{"key":"10.1016\/j.advms.2021.12.003_bib16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/09513590701297708","article-title":"Polycystic ovary syndrome and hyperprolactinemia are distinct entities","volume":"23","author":"Filho","year":"2007","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.advms.2021.12.003_bib17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3389\/fendo.2020.00263","article-title":"The association between prolactin and metabolic parameters in PCOS women: a retrospective analysis","volume":"11","author":"Yang","year":"2020","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.advms.2021.12.003_bib18","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/humrep\/deu133","article-title":"Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome","volume":"29","author":"Glintborg","year":"2014","journal-title":"Hum Reprod"},{"key":"10.1016\/j.advms.2021.12.003_bib19","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1172\/JCI20401","article-title":"Mechanisms for pituitary tumorigenesis: the plastic pituitary","volume":"112","author":"Melmed","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.advms.2021.12.003_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11102-005-5085-2","article-title":"Pharmacologic resistance in prolactinoma patients","volume":"8","author":"Molitch","year":"2005","journal-title":"Pituitary"},{"key":"10.1016\/j.advms.2021.12.003_bib21","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0188-4409(00)00059-X","article-title":"Hypothalamic dopaminergic tone and prolactin bioactivity in women with polycystic ovary syndrome","volume":"31","author":"Hernandez","year":"2000","journal-title":"Arch Med Res"},{"key":"10.1016\/j.advms.2021.12.003_bib22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0015-0282(16)47838-6","article-title":"Hyperprolactinemia in polycystic ovary syndrome","volume":"41","author":"Luciano","year":"1984","journal-title":"Fertil Steril"},{"key":"10.1016\/j.advms.2021.12.003_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem-52-2-231","article-title":"Increased luteinizing hormone sensitivity to dopamine inhibition in polycystic ovary syndrome","volume":"52","author":"Quigley","year":"1981","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.advms.2021.12.003_bib24","first-page":"179","article-title":"Common endocrine disorders associated with the polycystic ovary syndrome","volume":"19","author":"Abdelazim","year":"2020","journal-title":"Przeglad Menopauzalny"},{"key":"10.1016\/j.advms.2021.12.003_bib25","first-page":"1","article-title":"Expression patterns of ER\u03b166 and its novel variant isoform ER\u03b136 in lactotroph pituitary adenomas and associations with clinicopathological characteristics","author":"Mahboobifard","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.advms.2021.12.003_bib26","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1210\/edrv-16-3-322","article-title":"Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion","volume":"16","author":"Ehrman","year":"1995","journal-title":"Endocr Rev"},{"key":"10.1016\/j.advms.2021.12.003_bib27","series-title":"Clinical gynecologic endocrinology and infertility","author":"Fritz","year":"2012"},{"key":"10.1016\/j.advms.2021.12.003_bib28","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/BF03347025","article-title":"Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome?","volume":"26","author":"Bahceci","year":"2003","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.advms.2021.12.003_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7827-9-39","article-title":"The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study","volume":"9","author":"Tehrani","year":"2011","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1016\/j.advms.2021.12.003_bib30","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejogrb.2013.12.018","article-title":"To what extent does the use of the Rotterdam criteria affect the prevalence of polycystic ovary syndrome? A community-based study from the Southwest of Iran","volume":"174","author":"Rashidi","year":"2014","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.advms.2021.12.003_bib31","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/clinchem\/33.8.1372","article-title":"Total testosterone, free-androgen index, calculated free testosterone, and free testosterone by analog RIA compared in hirsute women and in otherwise-normal women with altered binding of sex-hormone-binding globulin","volume":"33","author":"WIlke","year":"1987","journal-title":"Clin Chem"},{"key":"10.1016\/j.advms.2021.12.003_bib32","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.1016\/j.advms.2021.12.003_bib33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2265.1986.tb00759.x","article-title":"Studies of prolactin secretion in polycystic ovary syndrome","volume":"24","author":"Murdoch","year":"1986","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.1016\/j.advms.2021.12.003_bib34","first-page":"579","article-title":"Prolactin release in polycystic ovary","volume":"55","author":"Falaschi","year":"1980","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.advms.2021.12.003_bib35","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0015-0282(16)57966-7","article-title":"Evidence that an altered prolactin release is consequent to abnormal ovarian activity in polycystic ovary syndrome","volume":"64","author":"Paoletti","year":"1995","journal-title":"Fertil Steril"},{"key":"10.1016\/j.advms.2021.12.003_bib36","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1093\/humrep\/16.11.2263","article-title":"Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome","volume":"16","author":"Papaleo","year":"2001","journal-title":"Hum Reprod"},{"key":"10.1016\/j.advms.2021.12.003_bib37","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000489264","article-title":"Interpretation of serum gonadotropin levels in hyperprolactinaemia","volume":"107","author":"Abbara","year":"2018","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.advms.2021.12.003_bib38","series-title":"Etiological diagnosis of hyperprolactinemia","first-page":"98","author":"Cortet-Rudelli","year":"2007"},{"key":"10.1016\/j.advms.2021.12.003_bib39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ajog.2011.12.010","article-title":"Prevalence of hyperprolactinemia in adolescents and young women with menstruation-related problems","volume":"206","author":"Lee","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.advms.2021.12.003_bib40","doi-asserted-by":"crossref","DOI":"10.1111\/eci.12961","article-title":"The value of prolactin in predicting prolactinomicronma in hyperprolactinaemic polycystic ovarian syndrome","volume":"48","author":"Kyritsi","year":"2018","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.advms.2021.12.003_bib41","series-title":"Can polycystic ovarian syndrome be cured? Unfolding the concept of secondary polycystic ovarian syndrome!","author":"Khadilkar","year":"2019"},{"key":"10.1016\/j.advms.2021.12.003_bib42","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.18295\/squmj.2019.19.02.008","article-title":"Aetiologies of Hyperprolactinaemia: a retrospective analysis from a tertiary healthcare centre","volume":"19","author":"Malik","year":"2019","journal-title":"Sultan Qaboos Univ Med J"},{"key":"10.1016\/j.advms.2021.12.003_bib43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.37557\/gjphm.v2i1.28","article-title":"The frequency of elevated prolactin level in polycystic ovary syndrome women (pcos) and its'effect on pregnancy rate","volume":"2","author":"Hassan","year":"2020","journal-title":"Global J Public Health Med"},{"key":"10.1016\/j.advms.2021.12.003_bib44","first-page":"370","article-title":"Comparison of the levels of LH and FSH, TSH, prolactin, progesterone and estradiol hormones between Iranian infertile women with polycystic ovary syndrome and healthy women","volume":"5","author":"Hashemi","year":"2016","journal-title":"Int J Med Res Health Sci"},{"key":"10.1016\/j.advms.2021.12.003_bib45","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1210\/jcem-62-2-348","article-title":"Inhibitory effect of bromocriptine treatment on luteinizing hormone secretion in polycystic ovary syndrome","volume":"62","author":"Falaschi","year":"1986","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.advms.2021.12.003_bib46","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF03348155","article-title":"Acute effects of L-dopa and bromocriptine on serum PRL, LH and FSH levels in patients with hyperprolactinemic and normoprolactinemic polycystic ovary syndrome","volume":"10","author":"Prelevi\u0107","year":"1987","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.advms.2021.12.003_bib47","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF03350674","article-title":"Prolactin pulsatility in polycystic ovarian disease","volume":"8","author":"Laatikainen","year":"1985","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.advms.2021.12.003_bib48","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2265.1988.tb01208.x","article-title":"Episodic pulsatile secretion of FSH, LH, prolactin, oestradiol, oestrone, and LH circadian variations in polycystic ovary syndrome","volume":"28","author":"Venturoli","year":"1988","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.1016\/j.advms.2021.12.003_bib49","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1210\/jcem-63-1-119","article-title":"A\u00a0double blind controlled study of the hormonal and clinical effects of bromocriptine in the polycystic ovary syndrome","volume":"63","author":"Buvat","year":"1986","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.advms.2021.12.003_bib50","first-page":"272","article-title":"A\u00a0prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptine in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level","volume":"47","author":"Parsanezhad","year":"2002","journal-title":"Int J Fertil Women's Med"},{"key":"10.1016\/j.advms.2021.12.003_bib51","series-title":"Williams textbook of endocrinology E-Book","author":"Melmed","year":"2015"},{"key":"10.1016\/j.advms.2021.12.003_bib52","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mce.2004.04.018","article-title":"Ovarian granulosa cell lines","volume":"228","author":"Havelock","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.advms.2021.12.003_bib53","doi-asserted-by":"crossref","first-page":"16057","DOI":"10.1038\/nrdp.2016.57","article-title":"Polycystic ovary syndrome","volume":"2","author":"Azziz","year":"2016","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.advms.2021.12.003_bib54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.rbmo.2016.04.007","article-title":"The role of AMH in the pathophysiology of polycystic ovarian syndrome","volume":"33","author":"Garg","year":"2016","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.advms.2021.12.003_bib55","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1196\/annals.1429.014","article-title":"The pathophysiology of amenorrhea in the adolescent","author":"Golden","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.advms.2021.12.003_bib56","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/humupd\/dmx013","article-title":"Is foetal hyperexposure to androgens a cause of PCOS?","volume":"23","author":"Filippou","year":"2017","journal-title":"Hum Reprod Update"},{"issue":"Suppl 1","key":"10.1016\/j.advms.2021.12.003_bib57","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.fertnstert.2006.05.001","article-title":"Gonadotropin dysfunction in women with polycystic ovary syndrome","volume":"86","author":"Taylor","year":"2006","journal-title":"Fertil Steril"},{"key":"10.1016\/j.advms.2021.12.003_bib58","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.fertnstert.2008.01.036","article-title":"Inappropriate gonadotropin secretion in polycystic ovary syndrome","volume":"91","author":"Hsu","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.advms.2021.12.003_bib59","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/humupd\/dml017","article-title":"The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome","volume":"12","author":"Blank","year":"2006","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.advms.2021.12.003_bib60","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1472-6483(10)60140-X","article-title":"LH as a diagnostic criterion for polycystic ovary syndrome in patients with WHO II oligo\/amenorrhoea","volume":"16","author":"Hendriks","year":"2008","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.advms.2021.12.003_bib61","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1210\/jc.2006-1054","article-title":"Oligoanovulation with polycystic ovaries but not overt hyperandrogenism","volume":"91","author":"Dewailly","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.advms.2021.12.003_bib62","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1210\/jc.2006-1327","article-title":"Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features","volume":"91","author":"Welt","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.advms.2021.12.003_bib63","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(76)91343-X","article-title":"Hyperprolactinaemia and luteal insufficiency","volume":"1","author":"Seppala","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.advms.2021.12.003_bib64","first-page":"486","article-title":"Prolactin hypersecretion and short luteal phase defects","volume":"47","author":"Corenblum","year":"1976","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.advms.2021.12.003_bib65","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/167132","article-title":"Macroprolactinemia: diagnostic, clinical, and pathogenic significance","volume":"2012","author":"Shimatsu","year":"2012","journal-title":"Clin Dev Immunol."},{"key":"10.1016\/j.advms.2021.12.003_bib66","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/cen.12266","article-title":"Evaluation of macroprolactinemia in 259 women under investigation for polycystic ovary syndrome","volume":"80","author":"Hayashida","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.advms.2021.12.003_bib67","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3109\/09513590903209329","article-title":"The role of serum PRL bioactivity evaluation in hyperprolactinaemic women with different menstrual disorders","volume":"25","author":"Kostrzak","year":"2009","journal-title":"Gynecol Endocrinol"}],"container-title":["Advances in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112621000572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112621000572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:40:31Z","timestamp":1761824431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1896112621000572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1896112621000572"],"URL":"https:\/\/doi.org\/10.1016\/j.advms.2021.12.003","relation":{},"ISSN":["1896-1126"],"issn-type":[{"value":"1896-1126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"To what extent does polycystic ovary syndrome influence the cut-off value of prolactin? Findings of a community-based study","name":"articletitle","label":"Article Title"},{"value":"Advances in Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.advms.2021.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Medical University of Bialystok. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}